Blood News and Research

RSS

Atrium Medical presents interim results from its COBEST clinical study at the 2009 VIVA meeting

Atrium Medical Corporation is proud to announce the release of the interim results from the COBEST clinical study. This study is to evaluate the use of bare metal stents vs. balloon expandable covered stents for the treatment of aorto-iliac occlusive disease. Prof. Patrice Mwipatayi of Royal Perth Hospital, Australia, presented interim data on the Covered versus Balloon Expandable Stent Trial known as COBEST at the 2009 VIVA (Vascular InterVentional Advances) meeting in Las Vegas.

17 Nov 2009

First Edition: November 17, 2009

Based on today's headlines, all eyes continue to be focused on the Senate -- where Democratic leaders are still waiting for the revised Congressional Budget Office analysis of their health bill and plotting about when to hold the first procedural vote on the measure.

17 Nov 2009

Th22 cell to control inflammation in body to help fight off infection discovered

A new type of immune cell that can be out of control in certain chronic inflammatory diseases, worsening the symptoms of conditions like psoriasis and asthma, is described for the first time in the Journal of Clinical Investigation.

17 Nov 2009

Scientists solve 50-year-old thalidomide puzzle

Research into the controversial drug thalidomide reveals that the mechanism through which the drug causes limb defects is the same process which causes it to damage internal organs and other tissues. The article, published in Bio-Essays, outlines the challenges surrounding thalidomide research and claims that confirmation of a 'common mechanism' could lead to new treatments for Leprosy, Crohn's Disease, AIDS and some forms of cancer..

17 Nov 2009

New proposal can have substantial implications on EU fertility treatment costs

With 900,000 assisted reproduction treatments annually such as IVF and intrauterine inseminations in Europe the Commission's proposal to screen both partners before each treatment could lead to costs of over EUR 140 million annually.

17 Nov 2009

Consortium to define new modalities for treating hypertension and associated vascular complications

Top Institute Pharma has formed a consortium with Actelion Pharmaceuticals Ltd, Erasmus Medical Centre and Maastricht University to define new modalities for the treatment of hypertension (high blood pressure) and associated vascular complications such as heart and kidney failure, myocardial infarction and stroke.

17 Nov 2009

Health Net’s MA product portfolio offers budget-friendly health plan choices to beneficiaries for 2010

With the kick-off of the Medicare Annual Election Period (AEP) this week, Health Net, Inc. reminds those eligible for Medicare that Health Net’s Medicare Advantage (MA) product portfolio offers a comprehensive range of budget-friendly health plan choices to beneficiaries for 2010.

17 Nov 2009

AACR-NCI-EORTC conference highlights major expansion in cancer drug pipeline

To highlight results of more recent research, the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics International Conference will host a press briefing on "Drugs in the Pipeline." Sara A. Courtneidge, Ph.D., D.Sc., professor and director of the Tumor Microenvironment Program, and director of academic affairs at the Burnham Institute for Medical Research, will moderate this press briefing.

17 Nov 2009

Recent developments at Burnham Institute for Medical Research

New antibiotics for methicillin-resistant Staphylococcus aureus (MRSA) and other pesky bacteria. Andrei Osterman and collaborators have used comparisons of bacterial genomes to identify new targets for antibiotics and produced first-generation chemical inhibitors of a class of bacterial enzymes, called NadDs (nicotinate mononucleotide adenylyltransferases).

17 Nov 2009

Global Alliance for Chronic Disease to fight against chronic non-communicable diseases

An alliance of institutions collectively managing an estimated 80 percent of all public health research funding worldwide today announced their first targets for concerted action in the fight against "chronic non-communicable diseases" (CNCDs).

17 Nov 2009

Uniformly structured radiological test result reporting decreases the accuracy of the reports

As many software companies work to create programs that will give uniform structure to the way radiological test results are reported, a new study by researchers at Wake Forest University School of Medicine shows that such a system does not improve, but rather decreases the completeness and accuracy of the reports.

17 Nov 2009

WHO urged to establish a schedule to phase out the use of dental mercury fillings as soon as possible

Today, at an expert meeting on the future use of dental fillings, a letter signed by over 70 non-governmental organisations from around the world was presented, calling on the World Health Organization (WHO) to establish a schedule to phase out the use of dental mercury fillings as soon as possible.

17 Nov 2009

Aterovax presents results of its sPLA2 activity test in the PEACE trial

Aterovax SA, a company developing innovative products for atherosclerosis, today announced data demonstrating that its blood test for secretory phospholipase A2 (sPLA2) activity significantly improves cardiovascular risk prediction in patients with stable coronary artery disease (CAD) over a 5 year period, independent of established risk markers, including C-reactive protein.

17 Nov 2009

New, reversible antiplatelet drug not superior than irreversible one in patients undergoing PCI

A new, reversible antiplatelet drug did not demonstrate superiority over a current irreversible one in reducing the composite of death, heart attack or ischemia-related revascularization in the 48 hours after angioplasty, researchers reported in a late-breaking clinical trial presentation at the American Heart Association's Scientific Sessions 2009.

17 Nov 2009

Upsher-Smith Laboratories publishes results of SLIM Study

Results of the SLIM Study ("Slo-Niacin® and Atorvastatin Treatment of Lipoproteins and Inflammatory Markers in Combined Hyperlipidemia") were recently published in the Journal of Clinical Lipidology.

17 Nov 2009

DNA banking: A step toward preserving history and improving the health of future generations

This Thanksgiving Day marks the sixth annual National Family History Day, a U.S. Department of Health and Human Services initiative to encourage families to discuss their health history. Holiday gatherings are excellent opportunities for discussing and documenting family disease backgrounds which can save the lives of loved ones through early detection and preventive measures.

17 Nov 2009

CD4 Initiative selects Zyomyx's CD4 POC technology as best for measuring CD4 T-cell count in HIV/AIDS patients

Zyomyx, Inc., a leader in chip-based bioanalysis technologies, today announced that its readerless CD4 point-of-care (POC) technology was selected by Imperial College London's CD4 Initiative as the best-performing POC test method for measuring CD4 T-cell count in HIV/AIDS patients. Zyomyx's CD4 assay is now the only remaining POC product being supported by the CD4 Initiative.

17 Nov 2009

VCU and RAA have improved resuscitation and survival rates for cardiac arrest patients

Virginia Commonwealth University Medical Center and the Richmond Ambulance Authority have improved resuscitation and survival rates dramatically for cardiac arrest patients by training and equipping paramedics to begin lowering a patient's body temperature in the field during resuscitation and following up at the hospital with a host of high-tech strategies to improve the odds of survival.

17 Nov 2009

ThromboGenics and BioInvent International present phase I results of novel anti-cancer monoclonal antibody

ThromboGenics NV and BioInvent International AB today announced positive results from a Phase I trial of their novel anti-cancer monoclonal antibody TB-403 in patients with advanced solid tumours. The results were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, U.S. TB-403 was well tolerated with no reported dose limiting toxicity. These positive data support progression of TB-403 and further development.

17 Nov 2009

BioSante Pharmaceuticals applauds Boehringer Ingelheim for developing a therapy to treat HSDD

BioSante Pharmaceuticals, Inc., a specialty pharmaceutical company developing products for female sexual health, including LibiGel® for the treatment of hypoactive sexual desire disorder (HSDD), applauds the efforts of Boehringer Ingelheim to develop a therapy to treat this unmet medical need.

17 Nov 2009

Blood News and Research

Atrium Medical presents interim results from its COBEST clinical study at the 2009 VIVA meeting

First Edition: November 17, 2009

Th22 cell to control inflammation in body to help fight off infection discovered

Scientists solve 50-year-old thalidomide puzzle

New proposal can have substantial implications on EU fertility treatment costs

Consortium to define new modalities for treating hypertension and associated vascular complications

Health Net’s MA product portfolio offers budget-friendly health plan choices to beneficiaries for 2010

AACR-NCI-EORTC conference highlights major expansion in cancer drug pipeline

Recent developments at Burnham Institute for Medical Research

Global Alliance for Chronic Disease to fight against chronic non-communicable diseases

Uniformly structured radiological test result reporting decreases the accuracy of the reports

WHO urged to establish a schedule to phase out the use of dental mercury fillings as soon as possible

Aterovax presents results of its sPLA2 activity test in the PEACE trial

New, reversible antiplatelet drug not superior than irreversible one in patients undergoing PCI

Upsher-Smith Laboratories publishes results of SLIM Study

DNA banking: A step toward preserving history and improving the health of future generations

CD4 Initiative selects Zyomyx's CD4 POC technology as best for measuring CD4 T-cell count in HIV/AIDS patients

VCU and RAA have improved resuscitation and survival rates for cardiac arrest patients

ThromboGenics and BioInvent International present phase I results of novel anti-cancer monoclonal antibody

BioSante Pharmaceuticals applauds Boehringer Ingelheim for developing a therapy to treat HSDD

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News